...
首页> 外文期刊>Advances in Experimental Medicine and Biology >Market Surveillance of In Vitro Diagnostics by the BfArM Until End 2010: Safety of IVD for Therapeutic Drug Monitoring
【24h】

Market Surveillance of In Vitro Diagnostics by the BfArM Until End 2010: Safety of IVD for Therapeutic Drug Monitoring

机译:截至2010年底,BfArM进行体外诊断的市场监测:用于治疗药物监测的IVD的安全性

获取原文
获取原文并翻译 | 示例

摘要

The European Directive 98/79/EC on in vitro diagnostic medical devices (IVD) regulates the marketing and post market surveillance of IVD in the European Economic Area. In cases of incidents and field corrective actions, the manufacturers have to inform the responsible Competent Authorities (CA). In Germany, the Federal Institute for Drugs and Medical Devices (BfArM) is the responsible CA for most IVD. In this study all notifications regarding IVD for therapeutic drug monitoring (TDM) between begin 1999 until end of 2010 were analysed. A total of 2,851 notifications were received, of which 65 were related to IVD for TDM included in this study (54 tests vs. 11 analysers). Reports were received from manufacturers (58), CAs (5 cases) and users (2 cases). Most frequently IVD used for TDM of toxicologically relevant substances, antibiotics, antiepileptics and immunosup-pressives were affected. Investigations of the manufacturers were able to identify the underlying root causes of product failures in 50 cases (76.9%), 40 (74.1%) of which were tests and 10 (90.9%) analysers. In 11 cases (16.9%, all tests), the root cause remained unclear and in 4 cases (6.2%, 3 tests, 1 analyser) a product failure was excluded. Product failures in tests were most commonly material defects (12 cases), interferences (7 cases) and manufacturing errors (7 cases), whereas in the analyser group software errors (5 cases) were most common. Corrective actions were performed in 56 cases (86.2%); 46 (85.2%) in tests, and 10 (90.9%) in analysers. In the group of tests these were predominantly (multiple entries) customer information (46 cases, mandatory in case of a recall), recall (29 cases), modifications in production or quality management (29 cases) and modifications of the instructions for use (9 cases). However, in the analyser group corrective actions were typically customer information (10 cases), recall (5 cases) and software-update (4 cases). The obtained data demonstrate that there are differences in the type of product failures between analysers and tests, which are followed by different corrective actions depending on the root causes of product failure accordingly. The results and the experience since 1999 suggest that the system for post marketing surveillance of IVD is an established tool to enhance product safety even though further optimisation is possible.
机译:关于体外诊断医疗器械(IVD)的欧洲指令98/79 / EC规范了欧洲经济区IVD的市场和售后监督。如果发生事故和采取现场纠正措施,制造商必须通知负责的主管当局(CA)。在德国,联邦药品和医疗器械研究所(BfArM)是大多数IVD的负责CA。在本研究中,分析了1999年初至2010年底之间有关IVD用于治疗药物监测(TDM)的所有通知。总共收到了2,851份通知,其中65份与这项研究中包括的TDM的IVD相关(54个测试对11个分析人员)。收到了来自制造商(58),CA(5例)和用户(2例)的报告。用于TDM的IVD最常用于毒理学相关物质,抗生素,抗癫痫药和免疫抑制剂。对制造商的调查能够确定50例(76.9%)产品故障的根本原因,其中40例(74.1%)是测试,而10例(90.9%)分析员。在11例(16.9%,所有测试)中,根本原因仍然不清楚,在4例(6.2%,3个测试,1个分析器)中,排除了产品故障。测试中的产品故障最常见是材料缺陷(12例),干扰(7例)和制造错误(7例),而在分析仪组中,软件错误(5例)是最常见的。纠正措施为56例(86.2%);测试中占46(85.2%),分析人员中占10(90.9%)。在测试组中,这些主要是(多次输入)客户信息(46例,在召回情况下是强制性的),召回(29例),生产或质量管理的变更(29例)和使用说明的变更( 9例)。但是,在分析器组中,纠正措施通常是客户信息(10例),召回(5例)和软件更新(4例)。所获得的数据表明,分析仪和测试之间的产品故障类型有所不同,然后根据产品故障的根本原因采取不同的纠正措施。自1999年以来的结果和经验表明,即使可以进行进一步优化,IVD的售后监控系统也是提高产品安全性的既定工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号